Skip to main content
Top
Published in: Pathology & Oncology Research 1/2017

01-01-2017 | Original Article

Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive Breast Cancer

Authors: Gaurav Thakral, Andrew Wey, Mobeen Rahman, Rui Fang, Christopher Lum

Published in: Pathology & Oncology Research | Issue 1/2017

Login to get access

Abstract

Breast cancer is the second leading cause of cancer mortality amongst American women. The HER2 gene encodes a cell surface receptor that affects cell proliferation and has been recognized as a diagnostic factor in treatment selection for invasive breast cancer. Examine accuracy in HER2 detection between manual count, computer assisted, and automated tiling algorithm. 42 randomly selected invasive breast cancer specimens were enumerated by fluorescence in situ hybridization (FISH)for HER2 and CEP17 markers using the Vysis HER2 assay (AbbotLaboratory, North Chicago, IL). Specimens were tested using three methods: Manual, computer assisted nuclei selection (Tissue FISH MetaSystems, Newton, MA), and automated enumeration (MetaSystems, Newton, MA). The greatest bias and widest agreement limits for HER2 and CEP17 were seen in Automatic versus Manual, the gold standard. HER2 values greater than 6 possessed the greatest bias and widest agreement limits. CEP17 comparison showed similar bias and agreement limits for each comparison. Kappa values indicated good agreement for all methods although Tissue FISH and Manual possessed better agreement. Higher agreement at lower HER2 & CEP17 count maybe due to fewer chromosomal aberrations, in which selection of field of views has less variation between methods. Alternatively, increased background signals seen in polyploidy may be responsible for the variations in signal count. Manual and Tissue FISH demonstrated good agreement amongst by both Altman Bland and Cohen’s Kappa. While the automatic method has good agreement at lower HER2, the sharp increase in variability at higher HER2 counts illustrates a limitation of the automatic method.
Literature
1.
go back to reference Humphrey LL, Helfand M, Chan BK, Woolf SH (2002) Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137(5 Part 1):347–360CrossRefPubMed Humphrey LL, Helfand M, Chan BK, Woolf SH (2002) Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137(5 Part 1):347–360CrossRefPubMed
2.
go back to reference Heim S, Mitelman F. (2011) Cancer cytogenetics: chromosomal and molecular genetic abberations of tumor cells: John Wiley & Sons Heim S, Mitelman F. (2011) Cancer cytogenetics: chromosomal and molecular genetic abberations of tumor cells: John Wiley & Sons
3.
go back to reference Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984 CrossRef Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 31(31):3997–4013. doi:10.​1200/​JCO.​2013.​50.​9984 CrossRef
4.
go back to reference Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672CrossRefPubMed Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672CrossRefPubMed
5.
go back to reference Hanna WM, Ruschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, et al. (2014) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol: an official journal of the United States and Canadian Academy of Pathology, Inc. 27(1):4–18. doi:10.1038/modpathol.2013.103 Hanna WM, Ruschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, et al. (2014) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol: an official journal of the United States and Canadian Academy of Pathology, Inc. 27(1):4–18. doi:10.​1038/​modpathol.​2013.​103
6.
go back to reference Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMed Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMed
7.
go back to reference Hicks DG, Tubbs RR. (2005) Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 36(3):250–261. doi:10.1016/j.humpath.2004.11.010. Hicks DG, Tubbs RR. (2005) Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 36(3):250–261. doi:10.​1016/​j.​humpath.​2004.​11.​010.
8.
go back to reference Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C. (2013) Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens. Diagn Pathol 8:17. doi:10.1186/1746-1596-8-17 Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C. (2013) Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens. Diagn Pathol 8:17. doi:10.​1186/​1746-1596-8-17
9.
go back to reference Myles P, Cui J. I. (2007) Using the bland–Altman method to measure agreement with repeated measures. Br J Anaesth 99(3):309–311. Myles P, Cui J. I. (2007) Using the bland–Altman method to measure agreement with repeated measures. Br J Anaesth 99(3):309–311.
10.
go back to reference Bland JM, Altman D. (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 327(8476):307–310. Bland JM, Altman D. (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 327(8476):307–310.
11.
go back to reference Viera AJ, Garrett JM. (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360–363. Viera AJ, Garrett JM. (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360–363.
12.
go back to reference Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–256. doi:10.5858/arpa.2013-0953-SA CrossRefPubMed Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–256. doi:10.​5858/​arpa.​2013-0953-SA CrossRefPubMed
Metadata
Title
Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive Breast Cancer
Authors
Gaurav Thakral
Andrew Wey
Mobeen Rahman
Rui Fang
Christopher Lum
Publication date
01-01-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0091-4

Other articles of this Issue 1/2017

Pathology & Oncology Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine